Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Guidance and quality standards
Awaiting development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Filter by title or keyword
Filter
Area of interest
Area of interest
COVID-19 (6)
Type
Type
Guidance (325)
Quality standard (30)
Guidance programme
Guidance programme
Diagnostics guidance (2)
Health technology evaluations (1)
Highly specialised technologies guidance (1)
Interventional procedures guidance (14)
Medical technologies guidance (4)
Technology appraisal guidance (304)
Apply filters
Showing 1 to 10 of 355
Guidance and quality standards awaiting development
Title
Type
10395 - Aprocitentan for treating resistant hypertension TS ID 10395
Technology appraisal guidance
Abatacept for treating active idiopathic inflammatory myopathies TS ID 10095
Technology appraisal guidance
Abdominal aortic aneurysm
Quality standard
Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer TS ID 11831
Technology appraisal guidance
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]
Technology appraisal guidance
Acalabrutinib for treating relapsed or refractory mantle cell lymphoma TS ID 11954
Technology appraisal guidance
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]
Technology appraisal guidance
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia TS ID 11768
Technology appraisal guidance
Acalabrutinib with venetoclax for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma TS ID 11823
Technology appraisal guidance
Acne
Quality standard
Current page
1
2
3
…
36
Page
1
of
36
Next page
Results per page
10
25
50
All
Back to top